Literature DB >> 6152730

Some regulatory and integrative aspects of purine nucleotide biosynthesis and its control: an overview.

R W Watts.   

Abstract

The regulation and integration of purine nucleotide biosynthesis is considered from the viewpoint of the main groups of reaction sequences involved and with respect to some specific organs and tissues. Inhibiting either IMP dehydrogenase or adenylosuccinate synthetase in rat liver in vitro reduced the rate of purine do novo synthesis with respect to the purine remaining in the tissue and did not materially affect the rate with respect to the purines extruded into the incubation medium. These results are considered in contrast to the results of previous studies in cultured lymphoblasts. The relative activities of purine de novo synthesis and of purine salvage have been assessed in different tissues by the activities of amidophosphoribosyltransferase and hypoxanthine phosphoribosyltransferase (HPRT), respectively. Changes in purine de novo synthesis as measured by [14C]formate incorporation into cellular purines were reflected in the amidophosphoribosyltransferase activities. The capacity of different tissues to synthesize purines de novo is widespread and the role of the liver as the main site of purine de novo synthesis in vivo and exporting purines to other tissues appears questionable. Regulatory mechanisms may well be tissue specific. The age-related changes in the activity of the purine de novo synthesis and purine salvage pathways, respectively, in the brain suggest that it is physiological or neuropharmacological functions of the developed brain rather than cell division and organogenesis which require a high level of purine salvage relative to purine de novo synthesis. This is compatible with the observation that purine de novo synthesis alone can meet the needs for additional purine nucleotides which lectin induced lymphocyte transformation involves. The mechanism whereby purine de novo synthesis is initiated during lectin induced lymphoblast transformation remains obscure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6152730     DOI: 10.1016/0065-2571(83)90007-9

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  4 in total

1.  AMPD2 regulates GTP synthesis and is mutated in a potentially treatable neurodegenerative brainstem disorder.

Authors:  Naiara Akizu; Vincent Cantagrel; Jana Schroth; Na Cai; Keith Vaux; Douglas McCloskey; Robert K Naviaux; Jeremy Van Vleet; Ali G Fenstermaker; Jennifer L Silhavy; Judith S Scheliga; Keiko Toyama; Hiroko Morisaki; Fatma M Sonmez; Figen Celep; Azza Oraby; Maha S Zaki; Raidah Al-Baradie; Eissa A Faqeih; Mohammed A M Saleh; Emily Spencer; Rasim Ozgur Rosti; Eric Scott; Elizabeth Nickerson; Stacey Gabriel; Takayuki Morisaki; Edward W Holmes; Joseph G Gleeson
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

2.  Phototransduction Influences Metabolic Flux and Nucleotide Metabolism in Mouse Retina.

Authors:  Jianhai Du; Austin Rountree; Whitney M Cleghorn; Laura Contreras; Ken J Lindsay; Martin Sadilek; Haiwei Gu; Danijel Djukovic; Dan Raftery; Jorgina Satrústegui; Mark Kanow; Lawrence Chan; Stephen H Tsang; Ian R Sweet; James B Hurley
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

3.  The purinosome, a multi-protein complex involved in the de novo biosynthesis of purines in humans.

Authors:  Hong Zhao; Jarrod B French; Ye Fang; Stephen J Benkovic
Journal:  Chem Commun (Camb)       Date:  2013-04-11       Impact factor: 6.222

4.  Immunosuppressant MPA Modulates Tight Junction through Epigenetic Activation of MLCK/MLC-2 Pathway via p38MAPK.

Authors:  Niamat Khan; D V Krishna Pantakani; Lutz Binder; Muhammad Qasim; Abdul R Asif
Journal:  Front Physiol       Date:  2015-12-22       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.